Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

第1相実施中（募集終了） NCT04535401

対象疾患	Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
相	第1相
スポンサー	National Cancer Institute (NCI)
ステータス	実施中（募集終了）
参加者数	10 名
介入（薬剤）	Biopsy, Biospecimen Collection, Diagnostic Imaging, Elimusertib, Fluorouracil
開始日	2021年8月13日
完了日	2025年2月19日
結果公開日	2026年7月13日

概要

This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started (primary site) to other places in the body (metastatic). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan, fluorouracil, and leucovorin, (called FOLFIRI in short) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BAY 1895344 in combination with FOLFIRI may help shrink advanced or metastatic stomach and/or intestinal cancer.

Maximum Tolerated Dose (MTD) of Elimusertib (BAY 1895344) in Combination With Irinotecan, Fluorouracil, and Leucovorin (FOLFIRI)

Up to 28 days · mg/m2

Elimusertib + Irinotecan + Fluorouracil + Leucovorin (FOLFIRI)	NA mg/m2

Patients Who Experienced DLTs

Up to 28 days · percentage of patients

Treatment (Elimusertib, FOLFIRI): DL-1	33.3 percentage of patients
Treatment (Elimusertib, FOLFIRI): DL-1B	66.7 percentage of patients
Treatment (Elimusertib, FOLFIRI): DL1	33.3 percentage of patients
Treatment (Elimusertib, FOLFIRI): DL1B	100 percentage of patients

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Ad — Hoffmann-La Roche
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patient — National Cancer Institute (NCI)
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Un — University of Southern California
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresecta — National Cancer Institute (NCI)
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients — National Cancer Institute (NCI)

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский